Antimicrobial resistance (AMR) has emerged as one of the most pressing global health threats of our time, directly causing and contributing to millions of deaths worldwide, as reported by the World Health Organization (WHO). Beyond the human toll, the economic impact is staggering. By 2050, AMR could add $1 trillion in healthcare costs annually and slash global gross domestic product (GDP) by up to $3.4 trillion per year by 2030. But amidst these daunting figures, a beacon of hope has appeared – bacteriophages (phages). In an era where AMR poses one of the greatest challenges in modern medicine, phages, viruses that specifically target bacteria, represent a revolutionary alternative to traditional antibiotics. A recent milestone in this field has been Portugal’s approval of customised bacteriophage therapies in hospital settings, setting Portugal to be only the third European country, alongside Belgium and France, to approve until now a guiding regulation for these new therapies (INFARMED, I.P. deliberation No. 112/CD/2024, November 15, 2024) for complex bacterial infections. This decision aligns closely with INL’s cutting-edge research on phages. Dr. Sanna Sillankorva, a tenured staff researcher from the Bañobre Research Group at INL has been instrumental in this progress. Her work focuses on isolating and […]
Read more